Company intelligence / Profile preview
Synthetic Design Lab
- Ownership
- Private
- Development stage
- Preclinical
Overview
Developing next-generation ADCs using proprietary SYNTHBODY platform aiming for ≥10x payload delivery improvement over existing therapies[1][4]
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Synthetic Design Lab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synthetic Design Lab.